Human Herpesvirus 8 (HHV8) Transmission and Related Morbidity in Organ Recipients
Célèste Lebbé(Inserm), C. Françès(Navarre Institute of Health Research), Sylvie Euvrard(Hospices Civils de Lyon), Didier Samuel(Hôpital Paul-Brousse), C. Legendre(Délégation Paris 5), A. Bigorie(Agence de la Biomédecine), Élisabeth Dussaix(Université Paris-Sud), Raphaël Porcher(Hotel Dieu Hospital), H. Creusvaux(Agence de la Biomédecine), Shaïda Varnous(Université Paris-Est Créteil), F. Agbalika(Inserm), Anne‐Geneviève Marcelin(Inserm)
Cited by 69
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k